The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: andrea.necchi@istitutotumori.mi.it.
Andrea
A
Necchi
Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Nicola
N
Nicolai
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Patrizia
P
Giannatempo
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniele
D
Raggi
Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rosalba
R
Miceli
Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Luigi
L
Mariani
Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Roberto
R
Salvioni
D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013736:Testicular Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
Chemotherapy; Germ cell tumor; Prognosis; Testicular cancer